PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+17.12%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.44B
AUM Growth
+$3.44B
(+1.8%)
Cap. Flow
-$426M
Cap. Flow
% of AUM
-12.37%
Top 10 Holdings %
Top 10 Hldgs %
43.73%
Holding
111
New
9
Increased
21
Reduced
33
Closed
19
Top Buys
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$114M |
| 2 |
Akero Therapeutics
AKRO
|
$66.2M |
| 3 |
Vir Biotechnology
VIR
|
$44.5M |
| 4 |
Medtronic
MDT
|
$41.1M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$35.2M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$153M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$137M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$80.3M |
| 4 |
Sanofi
SNY
|
$41.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$35.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Axsome Therapeutics
AXSM
$6.09B
| $19.5M | 0.56% |
+271,493
| New | +$19.5M |
|
52
Solid Biosciences
SLDB
$448M
| $18.3M | 0.53% |
3,495,933
| – | – |
|
53
Astria Therapeutics
ATXS
$394M
| $18.2M | 0.53% |
2,189,462
| – | – |
|
54
Artivion
AORT
$2.04B
| $16M | 0.46% |
931,352
-154,508
| -14% | -$2.66M |
|
55
Biomea Fusion
BMEA
$114M
| $15.7M | 0.46% |
716,441
+391,441
| +120% | +$8.59M |
|
|
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.6M | 0.45% |
+245,800
| New | +$15.6M |
|
57
Mirum Pharmaceuticals
MIRM
$3.75B
| $15.6M | 0.45% |
601,566
| – | – |
|
58
Tactile Systems Technology
TCMD
$295M
| $15M | 0.43% |
602,377
-37,500
| -6% | -$935K |
|
59
Orchestra BioMed
OBIO
$147M
| $14.4M | 0.42% |
2,052,868
-225,358
| -10% | -$1.58M |
|
60
Athira Pharma
ATHA
$15.5M
| $14.2M | 0.41% |
4,797,278
| – | – |
|
61
Axogen
AXGN
$718M
| $13.4M | 0.39% |
1,464,822
+55,031
| +4% | +$502K |
|
|
FUSN
62
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $12.8M | 0.37% |
2,751,395
-8,541
| -0.3% | -$39.9K |
|
63
Prothena Corp
PRTA
$452M
| $12.6M | 0.36% |
184,615
-53,031
| -22% | -$3.62M |
|
|
CMAX
64
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $11.9M | 0.34% |
3,817,404
+241,364
| +7% | +$751K |
|
65
Soleno Therapeutics
SLNO
$3.56B
| $9.47M | 0.27% |
+2,207,753
| New | +$9.47M |
|
66
Neurocrine Biosciences
NBIX
$13.5B
| $9.43M | 0.27% |
100,050
| – | – |
|
67
Sarepta Therapeutics
SRPT
$1.98B
| $9.28M | 0.27% |
81,074
-179,784
| -69% | -$20.6M |
|
68
Biohaven
BHVN
$1.71B
| $7.67M | 0.22% |
+320,820
| New | +$7.67M |
|
69
Viking Therapeutics
VKTX
$3.02B
| $7.15M | 0.21% |
441,147
-430,600
| -49% | -$6.98M |
|
70
X4 Pharmaceuticals
XFOR
$70M
| $6.88M | 0.2% |
3,545,454
-1,000,000
| -22% | -$1.94M |
|
|
ISEE
71
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.61M | 0.19% |
168,000
-332,000
| -66% | -$13.1M |
|
|
LABP
72
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $6.26M | 0.18% |
1,486,991
-13,382,924
| -90% | -$4 |
|
73
Tyra Biosciences
TYRA
$657M
| $6.13M | 0.18% |
360,000
-134,403
| -27% | -$2.29M |
|
|
NBTX
74
Nanobiotix
NBTX
$415M
| $5.37M | 0.16% |
1,059,800
| – | – |
|
|
VBIV
75
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $4.54M | 0.13% |
1,381,355
-50,953,647
| -97% | -$1.19M |
|